|
1. Kim JW, Kim SJ, Kim MR.
Leucocyte-rich and platelet-rich fibrin for the
treatment of bisphosphonate-related osteonecrosis
of the jaw: a prospective feasibility study. Br
J Oral Maxillofac Surg. 2014;52:854-59.
https://doi.org/10.1016/j.bjoms.2014.07.256
PMid:25138613
|
|
|
|
2. Park JH, Kim JW, Kim
SJ. Does the Addition of Bone Morphogenetic Protein
2 to Platelet-Rich Fibrin Improve Healing After
Treatment for Medication-Related Osteonecrosis of
the Jaw? J Oral Maxillofac Surg. 2017;75:1176-84.
PMid:28042979
|
|
|
|
|
3. Maluf G,
Pinho MC, Cunha SR, Santos PS, Fregnani ER. Surgery Combined with LPRF
in Denosumab Osteonecrosis of the Jaw: Case Report.
Braz Dent J. 2016;27:353-8.
https://doi.org/10.1590/0103-6440201600662
PMid:27224573
|
|
|
|
|
4. Pichardo SE, Richard
van Merkesteyn JP. Bisphosphonate-related
osteonecrosis of the jaws: spontaneous or dental
origin? Oral Surg Oral Med Oral Pathol Oral Radiol.
2013;116:287-92.
https://doi.org/10.1016/j.oooo.2013.05.005
PMid:23953415
|
|
|
|
|
5. Allen MR, Burr DB. The
pathogenesis of bisphosphonate-related
osteonecrosis of the jaw: so many hypotheses, so
few data. J Oral
Maxillofac Surg. 2009;67:61-70.
https://doi.org/10.1016/j.joms.2009.01.007
PMid:19371816
|
|
|
|
|
6. Ruggiero
SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T,
Mehrotra B, et al. American Association of
Oral and Maxillofacial Surgeons position paper on
medication-related osteonecrosis of the jaw--2014
update. J Oral
Maxillofac Surg. 2014;72:1938-56.
https://doi.org/10.1016/j.joms.2014.04.031
PMid:25234529
|
|
|
|
|
7. Yamashita J, McCauley
LK. Antiresorptives and osteonecrosis of the jaw. J
Evid Based Dent Pract. 2012;12:233-47.
https://doi.org/10.1016/S1532-3382(12)70046-5
PMid:23040351
|
|
|
|
|
8. Oliveira
CC, Brizeno LA, Sousa FB, Mota MR, Alves AP. Osteonecrosis of the jaw
induced by receptor activator of nuclear
factor-kappa B ligand (Denosumab). Med Oral Patol
Oral Cir Bucal. 2016;21:e431-9.
https://doi.org/10.4317/medoral.21044
PMid:26827069 PMCid:PMC4920456
|
|
|
|
|
9. Otto, S, Pautke, C.
Treatment of medication-related osteonecrosis of
the jaw. Medication Related Osteonecrosis of the
Jaws: Bisphosphonates, Denosumab and New Agents. Springer-Verlog
Berlin Heidelberg. 2015:79-92.
PMCid:PMC4429888
|
|
|
|
|
10. Yoneda T, Hagino H,
Sugimoto T, Ohta H, Takahashi S, Soen S, et al.
Antiresorptive agent-related osteonecrosis of the
jaw: Position Paper 2017 of the Japanese Allied
Committee on Osteonecrosis of the Jaw. J
Bone Miner Metab. 2017. J Bone Miner Metab. 2017;35:6-19.
https://doi.org/10.1007/s00774-016-0810-7
PMid:28035494
|
|
|
|
|
11. Lau AN, Adachi JD.
Resolution of osteonecrosis of the jaw after
teriparatide [recombinant human PTH-(1-34)] therapy.
J Rheumatol. 2009;36:1835-37.
https://doi.org/10.3899/jrheum.081176
PMid:19671824
|
|
|
|
|
12. Martins MA, Martins
MD, Lascala CA, Curi MM, Migliorati CA, Tenis CA,
et al. Association of laser phototherapy with PRP
improves healing of bisphosphonate-related
osteonecrosis of the jaws in cancer patients: a
preliminary study. Oral
Oncol. 2012;48:79-84.
https://doi.org/10.1016/j.oraloncology.2011.08.010
PMid:21940198
|
|
|
|
|
13. Curi MM, Cossolin GS,
Koga DH, Zardetto C, Christianini S, Feher O, et
al. Bisphosphonate-related osteonecrosis of the
jaws–an initial case series report of treatment
combining partial bone resection and autologous
platelet-rich plasma. J
Oral Maxillofac Surg. 2011;69:2465-72.
https://doi.org/10.1016/j.joms.2011.02.078
PMid:21763050
|
|
|
|
|
14.
Bocanegra-Pérez S, Vicente-Barrero M, Knezevic M,
Castellano-Navarro JM, Rodríguez-Bocanegra E,
Rodríguez-Millares J, et al. Use of platelet-rich
plasma in the treatment of bisphosphonate-related
osteonecrosis of the jaw. Int J Oral Maxillofac
Surg. 2012;41:1410-15.
https://doi.org/10.1016/j.ijom.2012.04.020
PMid:22647765
|
|
|
|
|
15. Mozzati M, Gallesio G,
Arata V, Pol R, Scoletta M. Platelet-rich therapies
in the treatment of intravenous
bisphosphonate-related osteonecrosis of the jaw: a
report of 32 cases. Oral
Oncol. 2012;48:469-74.
https://doi.org/10.1016/j.oraloncology.2011.12.004
PMid:22265335
|
|
|
|
|
16. Dohan Ehrenfest DM,
Rasmusson L, Albrektsson T. Classification of
platelet concentrates: from pure platelet-rich
plasma (P-PRP) to leucocyte- and platelet-rich
fibrin (L-PRF). Trends
Biotechnol. 2009;27:158-67.
https://doi.org/10.1016/j.tibtech.2008.11.009
PMid:19187989
|
|
|
|
|
17. Dinca O, Zurac S,
Staniceanu F, Bucur MB, Bodnar DC, Vladan C, et al.
Clinical and histopathological studies using
fibrin-rich 'plasma in the treatment of
biphosphonate-related osteonecrosis of the jaw. Rom
J Morphol Embryol. 2014;55:961-64.
PMid:25329128
|
|
|
|
|
18. Lesclous P, Grabar S,
Najm SA, Carrel JP, Lombardi T, Saffar JL, et al.
Relevance of surgical management of patients
affected by bisphosphonate-associated osteonecrosis
of the jaws. A prospective clinical and
radiological study. Clin oral Investig. 2014;18:391-99.
https://doi.org/10.1007/s00784-013-0979-2
PMid:23604698
|
|
|
|
|
19. Rupel K,
Ottaviani G, Gobbo M, Contardo L, Tirelli G,
Vescovi P, et al. A systematic review of
therapeutical approaches in bisphosphonates-related
osteonecrosis of the jaw (BRONJ). Oral
Oncol. 2014;50:1049-57.
https://doi.org/10.1016/j.oraloncology.2014.08.016
PMid:25240948
|
|